FREQUENCY OF HEPATITIS C SEROPOSITIVITY AMONG PATIENTS WITH TYPE 2 DIABETES MELLITUS

T TAJ; SH ELAHI; A ESSA; SM JUNAID

doi:10.54112/pjicm.v5i02.165

Authors

T TAJ Department of General Medicine, Lady Reading Hospital, Peshawar, Pakistan
SH ELAHI Department of General Medicine, Swat Medical Complex, Pakistan
A ESSA Department of General Medicine, MTI Dera Ismail Khan, Pakistan
SM JUNAID Private Clinic, Skin Sense Laser Clinic, Peshawar, Pakistan

DOI:

https://doi.org/10.54112/pjicm.v5i02.165

Keywords:

Hepatitis C Virus, Type 2 diabetes mellitus (T2DM), Patients, Seropositive

Abstract

Background: Hepatitis C virus (HCV) infection remains a global health burden, with an increased risk of chronic complications in patients with comorbidities. Type 2 diabetes mellitus (T2DM) has been associated with higher HCV prevalence, potentially due to shared risk factors and the impact of chronic HCV on glucose metabolism. Objective: To determine the frequency of hepatitis C seropositivity among patients with type 2 diabetes mellitus. Study Design: Cross-sectional study. Setting: Department of Medicine, Tertiary Care Hospital, Peshawar. Duration of Study: January 2025 to July 2025. Methods: A total of 178 patients, aged 21–70 years and of either gender, with a diagnosed type 2 diabetes mellitus, were enrolled. Patients with other liver diseases, renal disease, or cardiac disease were excluded from the study. Blood samples were collected and tested for HCV seropositivity using standard serological assays. Data were analyzed using SPSS version 23. Results: The mean age of the study population was 55.63 ± 9.46 years. Among the patients, 103 (57.9%) were female and 75 (42.1%) were male. The overall frequency of HCV seropositivity in type 2 diabetic patients was 27 (15.2%). Conclusion: The frequency of hepatitis C seropositivity in patients with type 2 diabetes mellitus was found to be 15.2%. This highlights the importance of routine HCV screening in diabetic populations to facilitate early diagnosis and management.

References

Chen Y, Ji H, Shao J, Jia Y, Bao Q, Zhu J, et al. Different hepatitis C virus infection statuses are associated with a significant risk of developing type 2 diabetes mellitus: a network meta-analysis. Dig Dis Sci. 2020;65(7):1940–1950. https://doi.org/10.1007/s10620-019-05918-7

Adinolfi LE, Petta S, Fracanzani AL, Nevola R, Coppola C, Narciso V, et al. Reduced incidence of type 2 diabetes in patients with chronic hepatitis C virus infection cleared by direct-acting antiviral therapy: a prospective study. Diabetes Obes Metab. 2020;22(12):2408–2416. https://doi.org/10.1111/dom.14168

Aldubaie MH, Suryavamshi PM, Irfan UM, Al-Hamed HA, Almogbel TA, Almatroudi A, et al. Prevalence of hepatitis C viral infection among diabetes mellitus patients in Qassim Region, Saudi Arabia. J Pure Appl Microbiol. 2023;17(3):1722–1736. https://doi.org/10.22207/JPAM.17.3.37

Abdo AA, Sanai FM, Al-Faleh FZ. Epidemiology of viral hepatitis in Saudi Arabia: are we off the hook? Saudi J Gastroenterol. 2012;18(6):349–357. https://doi.org/10.4103/1319-3767.103425

Nawaz A, Zaidi SF, Usmanghani K, Ahmad I. Concise review on the insight of hepatitis C. J Taibah Univ Med Sci. 2015;10(2):132–139. https://doi.org/10.1016/j.jtumed.2014.08.004

Alter MJ. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol. 2006;44(Suppl 1):S6–S9. https://doi.org/10.1016/j.jhep.2005.11.004

Alzahrani N. Hepatitis C virus, insulin resistance, and diabetes: a review. Microbiol Immunol. 2022;66(10):453–459. https://doi.org/10.1111/1348-0421.13051

Butt AA, Yan P, Aslam S, Shaikh OS, Abou-Samra AB. Hepatitis C virus treatment with directly acting agents reduces the risk of incident diabetes: results from ERCHIVES. Clin Infect Dis. 2020;70(6):1153–1160. https://doi.org/10.1093/cid/ciz304

Hammerstad SS, Grock SF, Lee HJ, Hasham A, Sundaram N, Tomer Y. Diabetes and hepatitis C: a two-way association. Front Endocrinol (Lausanne). 2015;6:134. https://doi.org/10.3389/fendo.2015.00134

Lai SW, Chen PC, Liao KF, Muo CH, Lin CC, Sung FC. Risk of hepatocellular carcinoma in diabetic patients and risk reduction associated with anti-diabetic therapy: a population-based cohort study. Am J Gastroenterol. 2012;107(1):46–52. https://doi.org/10.1038/ajg.2011.384

Veldt BJ, Chen W, Heathcote EJ, Wedemeyer H, Reichen J, Hofmann WP, et al. Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus. Hepatology. 2008;47(6):1856–1862. https://doi.org/10.1002/hep.22251

Kanwal N, Nasir B, Abrar MA, Kaukab I, Nawaz A, Murtaza G. Prevalence of hepatitis C in diabetic patients: a prospective study. Acta Pol Pharm. 2016;73(3):771–775. [No DOI assigned].

Akbar DH, Siddique AM, Ahmed MM. Prevalence of type-2 diabetes in patients with hepatitis C and B virus infection in Jeddah, Saudi Arabia. Med Princ Pract. 2002;11(2):82–85. https://doi.org/10.1159/000058012

Khan N, Khan N, Hussain J, Ullah H, Khan H. Frequency of hepatitis C in type 2 diabetics. Gomal J Med Sci. 2014;12(2):81–83. [No DOI assigned].

Yousaf Z, Anwar S, Imran F, Ahsan U, Dar YF, Jabeen K, et al. Frequency of type 2 diabetes mellitus among patients with hepatitis C virus infection. J Health Rehabil Res. 2024;4(1):1170–1174. https://doi.org/10.61919/jhrr.v4i1.563

Farshadpour F, Taherkhani R, Ravanbod MR, Eghbali SS. Prevalence and genotype distribution of hepatitis C virus infection among patients with type 2 diabetes mellitus. Med Princ Pract. 2018;27(4):308–316. https://doi.org/10.1159/000488985

Villar LM, Geloneze B, Vasques ACJ, Pires ML, Miguel JC, da Silva EF, et al. Prevalence of hepatitis B and hepatitis C among individuals with type 2 diabetes mellitus. PLoS One. 2019;14(2):e0211193. https://doi.org/10.1371/journal.pone.0211193

Laloo D, Walke P, Bhimo T, Prasad L, Ranabir S. Seroprevalence of hepatitis C infection in type 2 diabetes mellitus. Indian J Endocrinol Metab. 2015;19(2):296–299. https://doi.org/10.4103/2230-8210.149325

Eilah DT, Chamba NG, Sadiq AM, Mwasamwaja AO, Kimondo FC, Matay CD, et al. Seroprevalence and associated factors for hepatitis B and hepatitis C viral infection among patients with diabetes mellitus in Northern Tanzania. PLoS One. 2025;20(2):e0319198. https://doi.org/10.1371/journal.pone.0319198